1
/
of
2
Vinrab (Equine anti-rabies immunoglobulin)
Vinrab (Equine anti-rabies immunoglobulin)
Regular price
â±2,900.00 PHP
Regular price
Sale price
â±2,900.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Vinrab Equine Anti-Rabies Immunoglobulin: Post-Exposure Prophylaxis Solution
Vinrab is a pharmaceutical-grade equine anti-rabies immunoglobulin (ERIG) formulation designed for immediate post-exposure prophylaxis in individuals exposed to rabies through contact with rabid or suspected rabid animals. This passive immunization product delivers rapid antibody protection when administered promptly following potential rabies exposure.
Each milliliter of Vinrab contains not less than 200 I.U. of equine anti-rabies immunoglobulin fragments, derived from horse plasma and processed to provide potent viral neutralizing antibodies. The formulation includes glycine (22.50 mg/mL), sodium chloride (9 mg/mL), cresol B.P. as a preservative (less than 0.25% v/v), and water for injection, meeting pharmaceutical standards for safety and efficacy.
Vinrab functions as a critical component of comprehensive rabies post-exposure prophylaxis protocols. Unlike active vaccines that require time to generate immune response, ERIG provides immediate passive immunity, supplying pre-formed antibodies that neutralize rabies virus particles at the exposure site. For optimal protection, Vinrab is administered in conjunction with rabies vaccination schedules to establish both immediate and long-term immune defense.
This equine-derived immunoglobulin is particularly valuable in healthcare settings and endemic regions where human rabies immunoglobulin (HRIG) availability is limited or cost-prohibitive. Vinrab represents an essential therapeutic option for rabies prevention protocols in clinical and veterinary medicine.
Proper wound cleansing and timely administration of Vinrab following confirmed or suspected rabies exposure significantly improve treatment outcomes and prevent progression to fatal rabies encephalitis.
Vinrab is a pharmaceutical-grade equine anti-rabies immunoglobulin (ERIG) formulation designed for immediate post-exposure prophylaxis in individuals exposed to rabies through contact with rabid or suspected rabid animals. This passive immunization product delivers rapid antibody protection when administered promptly following potential rabies exposure.
Each milliliter of Vinrab contains not less than 200 I.U. of equine anti-rabies immunoglobulin fragments, derived from horse plasma and processed to provide potent viral neutralizing antibodies. The formulation includes glycine (22.50 mg/mL), sodium chloride (9 mg/mL), cresol B.P. as a preservative (less than 0.25% v/v), and water for injection, meeting pharmaceutical standards for safety and efficacy.
Vinrab functions as a critical component of comprehensive rabies post-exposure prophylaxis protocols. Unlike active vaccines that require time to generate immune response, ERIG provides immediate passive immunity, supplying pre-formed antibodies that neutralize rabies virus particles at the exposure site. For optimal protection, Vinrab is administered in conjunction with rabies vaccination schedules to establish both immediate and long-term immune defense.
This equine-derived immunoglobulin is particularly valuable in healthcare settings and endemic regions where human rabies immunoglobulin (HRIG) availability is limited or cost-prohibitive. Vinrab represents an essential therapeutic option for rabies prevention protocols in clinical and veterinary medicine.
Proper wound cleansing and timely administration of Vinrab following confirmed or suspected rabies exposure significantly improve treatment outcomes and prevent progression to fatal rabies encephalitis.
Share
